Watch the case study for Results of Phase 3 Studies for Acoltremon Ophtalmic Solution 0.003%, a Novel TRPM8 Agonist.

Study Objectives and Assessments: Comet-1: Evaluate the safety and efficacy of two doses of topical ophthalmic AR-15512 compared with vehicle in subjects with DED (Phase 2b); Comet-2&3: Evaluate…

Dry eye disease (DED) impacts approximately 30 million Americans and can have significant effects on their daily function and quality of life. Prescription drugs for DED in the United States…